View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jesper Ingildsen
  • Jesper Ingildsen

Embla Medical (Buy, TP: DKK34.00) - All eyes on tariffs

We expect a slower start to the year than previously, but a likely decent Q1 EBITDA margin, helped by last year’s cost cutting and product mix. We expect the focus to be on potential tariff effects, where we estimate a 10–15% hit on EPS mainly related to Bracing & Support (B&S) produced in China and sold to the US. We reiterate our BUY, but have reduced our target price to DKK34 (39).

ABGSC Construct. & Real Estate Research ... (+4)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Markus Henriksson
  • Oscar Lindquist
Ole Martin Westgaard
  • Ole Martin Westgaard

Europris (Buy, TP: NOK90.00) - Well-equipped for a harsher climate

Q1 earnings were below expectations, partly due to negative currency hedging effects in Norway and Sweden, and continued weakness in Sweden. However, we believe Europris is well-positioned for the current market climate and expect a successful turnaround in Sweden by 2028. We reiterate our BUY as we continue to find the valuation attractive, but have cut our target price to NOK90 (95) on lowered estimates.

ABGSC Retail Research ... (+3)
  • ABGSC Retail Research
  • Ali Shemmari
  • Petter Nystrøm
ABGSC Retail Research ... (+3)
  • ABGSC Retail Research
  • Ali Shemmari
  • Petter Nystrøm

EBIT below driven by SWE and GP

EBIT -37m vs cons +6m on lower sales in SWE and lower group gross profit. Gross profit hit by unrealized FX as the NOK has strengthened.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Financials Research ... (+5)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
  • Magnus Andersson
  • Patrik Brattelius
Niclas Gehin
  • Niclas Gehin

Kongsberg Gruppen (Hold, TP: NOK1450.00) - Less European exposure than...

We expect Q1 EBITDA of NOK2.2bn (results due at 07:00 CET on 8 May). Kongsberg Gruppen’s valuation premium to European defence peers has shrunk as peer multiples have converged on expectations of higher European defence spending. We believe this is warranted by its lower share of defence sales to EU countries. We continue to find the valuation demanding, while struggling to see negative share price catalysts. Hence, we reiterate our HOLD while we have raised our target price to NOK1,450 (1,300).

Simen Mortensen
  • Simen Mortensen

Mixed upside potential, despite market recovery expectations

Pent-up demand and falling interest rates remain the backbone for newbuild recovery expectations. However, as the recovery has not yet started, property developers screen as the most attractive long-term, but visibility remains mixed. Diversified construction companies are more attractive on near-term P/Es, although many seem to be fully valued on solid share-price performance over the past six months. We maintain a neutral sector view; NCC and Skanska are our top picks.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Martin Arnell
  • Martin Arnell

Betsson (Buy, TP: SEK190.00) - Attractive Latam growth exposure

We reiterate our BUY but have cut our target price to SEK190 (195) on lower estimates due to FX. We expect healthy Q1 revenue growth of 16% YOY, slightly offset by cost inflation, partly due to the recent technology bolt-on acquisition of Sporting Solutions. We maintain a positive view of rising EPS, FCF and net cash, boding well for potential further attractive acquisitions. The Q1 results are due at 07:30 CET on 29 April.

Miika Ihamaki
  • Miika Ihamaki

Nokian Tyres (Hold, TP: EUR6.30) - No clear road

While we acknowledge Nokian Tyres’ ‘local-to-local’ approach in the US may shelter it from worst tariff impacts, we believe increased uncertainty on consumer sentiment in North America could lead to weaker demand for its high-value premium range in the short term, raising the risk of fixed-cost under-absorption and partly offsetting potentially better EBIT drop-through from Romania (Q2 onwards). We reiterate our HOLD, but have cut our target price to EUR6.3 (6.7), following a c9% clean EBIT cut ...

ABGSC Retail Research ... (+3)
  • ABGSC Retail Research
  • Ali Shemmari
  • Petter Nystrøm
Simen Mortensen
  • Simen Mortensen

Jm Ab (Buy, TP: SEK170.00) - BUY on the dip

JM’s share price has been volatile over the past three years, trading in waves on recovery expectations. As the Swedish residential market has yet to recover, expectations have recently fallen further, and the stock has reached old lows. However, we expect a market recovery in late-2025 and 2026, and we believe this has created an attractive entry point. KPIs (unit sales and unit starts) are our Q1 focus point, as profits are still affected by cycle lows and a trailing profit recognition. We hav...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch